Cargando…

Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer

BACKGROUND: Trophoblast cell-surface antigen 2 (TROP2) is related to tumor proliferation enhancement and poor prognosis. An antibody targeting TROP2 was developed to treat metastatic triple-negative breast cancer (TNBC) which has a limited treatment modality. To characterize the TROP2 expressing tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeon, Yeonjin, Jo, Uiree, Hong, Jongmoo, Gong, Gyungyub, Lee, Hee Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509625/ https://www.ncbi.nlm.nih.gov/pubmed/36153494 http://dx.doi.org/10.1186/s12885-022-10076-7

Ejemplares similares

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
por: Goldenberg, David M., et al.
Publicado: (2018)

Antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (Trop-2) and precision treatment of breast cancer
por: Stenvang, Jan, et al.
Publicado: (2022)

Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer
por: Matusz-Fisher, Ashley, et al.
Publicado: (2022)

AB007. Expression of trophoblastic antigen 2 (Trop2) in thymic epithelial tumors
por: Yeung, Vincent, et al.
Publicado: (2022)

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus
por: Hoppe, Sascha, et al.
Publicado: (2022)

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
por: Cardillo, Thomas M., et al.
Publicado: (2020)

Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer
por: Izci, Hava, et al.
Publicado: (2022)

Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target
por: Wolber, Philipp, et al.
Publicado: (2021)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Bravaccini, Sara, et al.
Publicado: (2021)

Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
por: Liu, Donglin, et al.
Publicado: (2014)

Association of cyclooxygenase-2 expression with endoplasmic reticulum stress and autophagy in triple-negative breast cancer
por: Lee, Haechan, et al.
Publicado: (2023)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021)

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
por: Zeybek, Burak, et al.
Publicado: (2020)

Trop-2 Is a Determinant of Breast Cancer Survival
por: Ambrogi, Federico, et al.
Publicado: (2014)

Trop-2 as a Therapeutic Target in Breast Cancer
por: Sakach, Elizabeth, et al.
Publicado: (2022)

Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
por: Lee, Miseon, et al.
Publicado: (2019)

Correction: Trop-2 Is a Determinant of Breast Cancer Survival
Publicado: (2014)

TROP2 methylation and expression in tamoxifen-resistant breast cancer
por: Zimmers, Stephanie M., et al.
Publicado: (2018)

TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer
por: Liu, Xiaoyue, et al.
Publicado: (2022)

Prediction of prognostic signatures in triple-negative breast cancer based on the differential expression analysis via NanoString nCounter immune panel
por: Lim, Gyeong Back, et al.
Publicado: (2020)

Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer
por: Park, In Ah, et al.
Publicado: (2016)

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Development and characterization of TrMab-6, a novel anti-TROP2 monoclonal antibody for antigen detection in breast cancer
por: Sayama, Yusuke, et al.
Publicado: (2021)

Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements
por: Yao, Liqin, et al.
Publicado: (2023)

Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling
por: Park, In Ah, et al.
Publicado: (2017)

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas
por: Xu, Peng, et al.
Publicado: (2017)

Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2
por: Sun, Meng, et al.
Publicado: (2021)

The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms
por: Liu, Haiyan, et al.
Publicado: (2017)

Targeting Trop-2 in solid tumors: future prospects
por: Zaman, Saif, et al.
Publicado: (2019)

Trop2: Jack of All Trades, Master of None
por: Lenárt, Sára, et al.
Publicado: (2020)

TROP2 modulates the progression in papillary thyroid carcinoma
por: Sun, Huali, et al.
Publicado: (2021)

TROP2 Expression in Sebaceous and Sweat Gland Carcinoma
por: Ito, Takamichi, et al.
Publicado: (2022)

Clinico‐cytopathologic analysis of 574 Pericardial Effusion Specimens: Application of the international system for reporting serous fluid cytopathology (ISRSFC) and long‐term clinical follow‐up
por: Song, Min Jeong, et al.
Publicado: (2021)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
por: Song, In Hye, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e3pbma3h18s6l803rdfu9jguvk